Molecular subtypes of breast cancer are defined on the basis of gene expression and genomic/epigenetic pattern differences. Different subtypes are thought to originate from distinct cell lineages, but the early activation of an oncogene could also play a role. It is difficult to discriminate the respective inputs of oncogene activation or cell type of origin. In this work, we wished to determine whether activation of distinct oncogenic pathways in human mammary epithelial cells (HMEC) could lead to different patterns of genetic and epigenetic changes. To this aim, we transduced shp53 immortalized HMECs in parallel with the CCNE1, WNT1 and RASv12 oncogenes which activate distinct oncogenic pathways and characterized them at sequential stages of transformation for changes in their genetic and epigenetic profiles. We show that initial activation of CCNE1, WNT1 and RASv12, in shp53 HMECs results in different and reproducible changes in mRNA and miRNA expression, copy number alterations (CNA) and DNA methylation profiles.
Introduction
Genetic instability lies at the core of neoplastic development with up to 85% of human cancers showing loss of chromosome integrity at varying levels such as aberrant copy numbers and aneuploidy.
Chromosomal instability has been observed in early stages of cancer 1 and rearrangement intensity correlated with disease aggressiveness 2 . In addition to structural defects, cancer genomes undergo important epigenetic changes occurring at the chromatin and DNA levels 3 . At the DNA level, cancer associated epigenetic modifications involve genome wide cytosine methylation changes corresponding to demethylation of repetitive DNA sequences and hypermethylation of CpG enriched sequences 4, 5 .
Genetic instability results in stochastically occurring aberrations, of which a fraction will be selected according to the survival or growth advantage they confer. Hence, in tumors profiles of somatically acquired genetic and epigenetic changes and associated RNA expression modifications reflect the combined interactions of genetic instability and selective pressure. As a consequence, recurrent profiles of genomic and epigenetic aberrations should be structured around anomalies that confer maximum advantage in a given tissue and environment. Noticeably, cancers of distinct anatomical origins exhibit quite different profiles of genomic and epigenetic anomalies 6 . Recent work, based on human open reading frame library screening in 3 different cell types to identify proliferation drivers, elegantly showed the existence of a tissue specific selection for gains of function and loss of tumor suppressors 7 .
In breast cancer, molecular subtypes were defined on the basis of RNA expression, as well as of genomic anomalies and DNA methylation differences [8] [9] [10] [11] . Although definitive proof is still missing, it is generally proposed that the genetic and epigenetic differences in different breast tumor subtypes are dictated by distinct cell types of origin 8, 9 . Founding events due to early activation of distinct oncogenic pathways in a single cell type could also have an impact on genomic and epigenetic changes and induce the selection of anomalies functionally coherent with the activated pathway [12] [13] [14] [15] . This is supported by studies showing that expression of RASv12 and of BRAFv600 resulted in the transcriptional repression and hypermethylation of distinct gene sets, involving different cascades of repressors and DNA methylases 16, 17 . Yet, it has not been experimentally demonstrated that distinct oncogenic events could lead to specific genomic rearrangements.
In this work, we sought to determine the impact of the early activation of distinct oncogenic pathways on genomic and epigenetic changes in immortalized human mammary epithelial cells (HMECs). To this aim, we adapted a previously devised experimental scheme 18 and overexpressed by retroviral transduction three oncogenes WNT1, CCNE1 and RASv12, known to activate different oncogenic pathways, in shp53 immortalized human HMECs. Epigenetic and genetic changes were then monitored at different steps of cancer progression. The sequence of genetic and epigenetic alterations accompanying the transition between the normal and transformed states show that activation of these distinct oncogenes leads to the emergence of distinct and specific profiles of changes. These results thus support a model in which genetic and epigenetic changes in cancer cells reflect adaptive responses to the oncogenic driver.
Material and Methods

HMEC models
Human Mammary Epithelial Cells (HMECs) were isolated from mammary gland explants obtained from plastic surgical after informed consent from the patient. This work was approved by the Ethics committee of the University of Montpellier. Cell suspensions were produced by mechanical and enzymatic dissociation with 1% collagenase. After elimination of fibroblasts, HMECs were cultured at 37°C in 5% CO2, in conditioned MEBM medium supplemented with antibiotics (MEGM single Quots, Lonza, Levallois-Perret, France). Primary HMECs were transduced with amphotropic retroviral supernatants corresponding to: pSUPER.retro.hygro-shp53, pBABE.neo-CCNE1, pLNC-WNT1, pBABE.puro-HRASV12 followed by 3 weeks of antibiotic selection. This project has been reviewed and approved by the Ethics committee of the University of Montpellier.
β-galactosidase senescence test
β-galactosidase activity was assay by histochemistry using the Senescence Cells Histochemical Staining kit (Sigma-Aldrich, St Quentin Fallavier, France) following manufacturer's instructions. β-galactosidase positive cells were quantified under the microscope in duplicate on 400 cells minimum.
Telomeric restriction fragment (TRF) analysis and telomerase activity test and chromosome counts
TRF were purified using the TeloTAGGG Telomere Length Assay (Sigma-Aldrich, St Quentin Fallavier, France) following manufacturer's instructions. TRF sizes determined by 0.8% agarose gel electrophoresis and Southern blotting. The Nylon membrane was hybridized telomeric DNA probe labeled with digoxigenine and revealed with anti-DIG antibodies coupled alcalin phosphatase and chemioluminescence. Medium TRF size was calculated using TRF=Σ(ODi)/Σ(ODi/Li) (ODi= optical density at i, Li= size at i) Telomerase activity was measured on 2x10 5 cells with the TeloTAGGG Telomerase PCR ELISA kit (Sigma-Aldrich, St Quentin Fallavier, France) following manufacturer's instructions.
Anchorage independence growth (AIG)
AIG was determined in 6 well plates containing 2 layers of low melting point agarose in MEBM (Lonza) at 0.75% and 0.45% on top. 15000 cells/well were seeded and plates incubated for 5 weeks at 37°C in 5% CO2.
Colonies were visualized using 0.01% cristal violet and counted. Prior staining colonies were isolated and put in culture to generate the Soft Agar (SA) clones. Tumorigenicity 1.5 or 5x10 6 cells resuspended in a 1:1 Matrigel/PBS solution were injected subcutaneously in Swiss nude or SCID beige mice (Harlan/Envigo, Garnat France). Each subline tested was injected in 6 animals in parallel and tumor growth monitored for 5 months before animals were sacrificed. In vivo experiments were systematically reviewed and approved by an internal animal ethics committee and the University of Montpellier animal ethics committee.
DNA and RNA extraction
DNA and RNA were isolated using the QIAmp DNA Mini kit and Rneasy Mini Kit (Qiagen S.A. France, Courtaboeuf, France). Each DNA sample was quantified by nanospectrophotometry (NanoView, GE Healthcare, Orsay, France) and qualified by 0.8% agarose electrophoresis. Qualification of mRNA was performed using a Bioanalyser (Agilent, Santa Clara, CA, USA).
Array-CGH and mRNA expression profiling
Array-CGH was done using HG18 CGH 385K Whole Genome v2.0 array (Roche NimbleGen, Madison, WI, USA). Methods and analysis are described in detail in the Supplementary Methods.
miR expression profiling
Biotinylated cRNA were prepared according to the Affymetrix IVT Express protocol. Detailed description of the methods is provided in the Supplementary Methods.
DNA methylation profiling
RRBS libraries were prepared as previously described 19 . Detailed description of the experimental method and DMR selection approach are available in the Supplementary Methods.
MoGSA
To integrate the omics data of different origins (CNA, mIR and mRNA and DNA Methylation), we used the MoGSA package (Meng, 2017a,b) to identify Joint Patterns Across Multiple Omics Data Sets. More detailed description is available in the Supplementary Methods.
Immunofluorescence
Cells were seeded onto glass slides and grown to reach 50-60% confluence. Prior immunofluorescence cells were fixed with either 2% paraformaldéhyde or with ice cold methanol and permeabilized with 1% PBS-Triton and rinsed with 2% serum-PBS before incubation with the primary antibody, being rinsed in 2% serum-PBS and stained with DAPI and incubated with the secondary antibody. γH2AX/53BP1 foci were counted in triplicate on 400 nuclei. Antibodies are listed in the S Appendix.
High throughput data analysis
Detailed methods are presented in the Supporting Information 1. Raw array and RRBS data can be accessed at GSE114849 (see Supporting Information Supplementary Methods).
Results
Establishment of stepwise transformation cell models
Primary HMEC were isolated from fresh mammary tissue obtained from donors undergoing reductive plastic surgery (Supplementary Methods). We obtained 3 stable cell cultures that were propagated for at least 15 passages before cells started showing signs of senescence (reduced proliferation, large vacuoles and positive β-galactosidase staining) (Supporting Information Fig.1A ). Of the 3 primary HMEC lines, we selected the R2 line to establish our models of stepwise cell transformation. Cells were genetically modified by sequential retroviral transductions with defined genetic elements ( Fig.1A ). In the first step (immortalization), we transduced a vector expressing an shRNA targeting the TP53 gene (designated shp53 hereafter), which plays a key role in the senescence barrier. The shp53 efficiently knocked-down p53 protein expression and signaling (Supporting Information Fig.2 ) and cells grew rapidly. We derived three stable shp53 HMEC sublines that were used as models hereafter. The shp53 sublines showed reduced βgalactosidase staining, re-expression of the endogenous hTERT and stabilization of telomere length, indicating that the senescence program had been overcome spontaneously ( Fig or HRAS v12 , 3 oncogenes belonging to distinct signaling pathways. Several independent sublines were derived for each oncogenic situation (shp53-WNT1, shp53-CCNE1, shp53-RAS). Each subline was then seeded in soft agar to determine anchorage independent growth as a standard read out of in vitro transformation (Supporting Information Fig.1D ). Cell clones were isolated from soft agar foci and expanded (shp53-WNT1.SA, shp53-CCNE1.SA, shp53-RAS.SA). In total, we established 16 HMEC sublines (see Supplementary methods) corresponding to different steps of cancer transformation; immortalized (shp53), pre-transformed (shp53-oncogene) and transformed (shp53-oncogene.SA). However, it is of note that none of the shp53-oncogene.SA formed tumors in immunocompromised mice even after injection of up to 5 x 10 6 cells (Supporting Information Fig.1E ).
Genetic instability in the immortalized and transformed cell lines
We first analyzed the different HMEC sublines by array-CGH. Using the fraction of the genome involved in copy number alterations (CNAs) as a metric, we noted that the level of genetic instability gradually increased from 2 to 6% in the immortalized shp53 to 12 to 13% in the shp53-WNT1, shp53-CCNE1 and shp53-RAS and reached up to 22 and 27% in shp53-WNT1.SA and shp53-CCNE1.SA, respectively ( Fig.1D ).
Interestingly, patterns of CNA progression were coherent with ploidy changes. Metaphase spreads of shp53 and shp53-RAS sublines showed 92 chromosomes indicating tetraploidy, while, shp53-CCNE1 and shp53-WNT1 sublines became aneuploid showing 78 to 110 chromosomes ( Fig.1E ). To determine whether increased CNA levels were associated with increased genetic stress, we performed immunofluorescence staining of γH2Ax and 53BP1 in R2, shp53 and shp53-oncogene HMECs (Supporting Information Fig.3A-B ).
Two types of γH2Ax staining patterns were observed; nuclear foci, considered as markers of DNA breaks, and pan-nuclear staining, which has been proposed to reveal widespread replication stress in the absence of double strand breaks 23 . Immortalized shp53 HMECs predominantly showed pan-nuclear γH2AX staining and low levels of γH2Ax and 53BP1 foci, suggesting an elevation of genetic stress but low levels of DNA breaks in these cells. This contrasted with shp53-CCNE1 and shp53-WNT1, which essentially displayed γH2Ax and 53BP1 nuclear foci (Supporting Information Fig.3A-B ), consistent with a significant increase of DNA breaks confirmed by comet-assay (Supporting Information Fig.3C -D). Of note, shp53-RAS showed distinctly lower levels of γH2Ax and 53BP1 nuclear foci and low levels of DNA breaks by comet-assay relative to shp53-CCNE1 and shp53-WNT1.
Immortalized and transformed HMECs form 3 distinct clusters defined by the activated oncogene
Next, we determined whether the different immortalized and transformed HMEC sublines presented distinct profiles of genetic and epigenetic anomalies. Copy Number Alterations (CNA), DNA Methylation, miRNA (miR) and mRNA expression levels were determined at different steps of cell immortalization and transformation. To integrate these data corresponding to diverse molecular features and different technological platforms, we used moCluster (moGSA package), allowing to produce integrative clustering on multiple omics data. This approach is based on multivariate latent variable decomposition to discover correlated global variance structure across datasets 24 .
Two independent biological replicates of each immortalization or transformation step, (R2, shp53, shp53-WNT1, shp53-CCNE1, shp53-RAS and shp53-WNT1.SA, shp53-CCNE1.SA, shp53-RAS.SA HMECs) were included in this analysis. These analyses pointed at similarities and differences between distinct sublines and stages of transformation. These were determined by means of Principal Component Analysis (PCA).
Changes defining the most variant PCA vector were subsequently analyzed by Ward clustering. The combined analysis of the four datasets (CNA, DNA methylation, mRNA and miRNA expression) defined 3 clusters ( Fig.2A ). The first one, at the trunk, organized around R2 and shp53 early and late passages. The second corresponded to the four shp53-RAS sublines. The third cluster included shp53-WNT1 and shp53-CCNE1 sublines ( Fig.2A ). The number of clusters was confirmed by Nbclust (Supporting Information Fig.4 and Supplementary methods). Altogether, these analyses revealed that the HMEC sublines transduced with different genetic elements showed clear differences in their genetic and epigenetic patterns. We next analyzed CNAs, DNA methylation, mRNA and miRNA datasets individually to verify whether pattern differences applied similarly to all datasets.
Overexpression of CCNE1, WNT1 or HRAS v12 oncogenes in immortalized HMECs result in distinct profiles of copy number alterations
Genomic regions involved in CNAs were identified with the Nexus 7.5 Software (Biodiscovery, CA., USA) and
only CNAs covering at least 2 Mb were used in the moGSA analysis. PCA classification of HMEC sublines singled out three clusters. Cluster 1 positioned at the trunk encompassed R2 and shp53 replicates, cluster 2 formed by the shp53-RAS and shp53-RAS.SA sublines and a more dispersed cluster 3 comprising shp53-WNT1, shp53-CCNE1, shp53-WNT1.SA and shp53-CCNE1.SA (Fig.2B ). The distance along the PC1 vector in the principal component analysis, separating cluster 2 from cluster 3, illustrated the strong differences at the CNA level between the RAS and the WNT1 or CCNE1 transformed sublines ( Fig.2B) .
A clustering analysis of the CNAs defining the PC1 vector identified co-occurring loss of chromosome 4, loss at 8p and gain at 8q as the most significant anomalies characterizing the shp53-RAS HMECs (Fig.2C ). Other events were gains at 12q and losses at 14 and 18q (Supporting Information Fig.5A-B ). In clear contrast,
shp53-WNT1 and shp53-CCNE1 HMECs were characterized by losses at chromosomes 2, 3 and 6, as well as focal gains at 11q13 and 20q13 ( Fig.2C and Supporting Information Fig.5A-B ). Interestingly, whereas the pre-transformed shp53-RAS showed little difference with their transformed shp53-RAS.SA counterpart, significant deviation was detected between shp53-CCNE1 and shp53-CCNE1.SA, as well as between shp53-WNT1 and shp53-WNT1.SA, with additional gains at chromosome 11q13-q14 and 20q11-q13, respectively ( Fig.2C ). These data indicated increased genetic instability in shp53-CCNE1.SA and shp53-WNT1.SA, whereas this was not the case when shp53-RAS were compared with shp53-RAS.SA ( Fig.1D and Fig.2C ). Altogether, both CNA and DNA methylation profiles indicate that an oncogenic form of RAS induces specific genomic and epigenetic alterations, that markedly differ from those induced by WNT1 or CCNE1, whose profiles co-clustered in both classifications.
Overexpression of CCNE1, WNT1 or HRAS v12 oncogenes in immortalized HMECs result in distinct profiles
Overexpression of CCNE1, WNT1, or HaRAS v12 oncogenes in Shp53 HMECs result in distinct transcriptional programs and phenotypical cell fates.
As observed with CNA and DNA methylation profiles, cluster analyses of both miR and mRNA expression profiles clearly distinguished the RAS and CCNE1/WNT1 transformed cells in two separate clusters ( Fig.3C and Fig.3E ). Many genes presented an inverted pattern of expression in the RAS compared with the CCNE1/WNT1 sublines in the Ward clustering analysis of miR and mRNA expression changes ( Fig.3D and Fig.3F ). GeneGo Metacore (Thomson Reuter) network analyses of the miR and mRNA gene lists that discriminated cluster 2 and cluster 3 identified several differentially activated functional gene networks.
The miR data pointed at strong differences in EMT-associated pathways, illustrated by the level of miR200c, a key regulator of the EMT transcription factor ZEB1 25 , and the mesenchymal cell-specific miR143/miR145, that differed markedly between RAS and CCNE1/WNT1 cells 26 (Supporting Information Fig.7 ).
Morphological features (cuboidal vs. fusiform) and immunostaining of sublines with epithelial E-Cadherin (ECAD) and mesenchymal Vimentin (VIM) markers, confirmed that primary R2, immortalized shp53, and transformed shp53-CCNE1 and shp53-WNT1 cells all maintained an epithelial phenotype (cuboid, ECAD high , VIM low ), while shp53-RAS cells were fusiform, ECAD-negative and VIM high indicating a clear mesenchymal conversion (Supporting Information Fig.8 ).
Chronology of the genetic and epigenetic changes occurring during transformation of HMECs.
Monitoring the genetic and epigenetic changes occurring at each step of the cell transformation process allowed us to reconstruct their chronology. This could be inferred from the PC2 vectors in the PCA classifications. Starting from normal R2 primary cells, moving to early and late immortalized cells and progressively to soft agar subclones, we noted that the different sublines bore different positions in these classifications according to the dataset considered. Indeed, the CNA classification indicated that R2 coclustered with early and late passage shp53 immortalized cells (Fig.2B) , while that based on miR indicated that primary R2 were clearly distinct from all the other sublines (Fig.3C) . In contrast, the mRNA and DMR based classifications showed that primary R2 co-clustered with early passage shp53 cells, whereas late passage shp53 were positioned closer to shp53-CCNE1 and shp53-WNT1, indicating a shift between early and late passages shp53 HMECs (Fig.3A and 3E) .
These results suggest a temporal hierarchy of the genetic and epigenetic events that primed transformation in our models. Upon p53 inactivation in HMECs, miR expression appeared to be the first modified, whilst the modification of mRNA expression profiles and massive modifications of the methylation landscape occurred later. Upon transduction with RAS, WNT1 or CCNE1, additional DNA methylation changes occurred concomitantly with modifications in mRNA expression. Copy number changes emerged last and underwent a clear selection process during soft agar cloning ( Fig.2B and Supporting Information Fig.5A ).
Impact of copy number changes and differential DNA methylation on gene expression.
Next, we identified the genes in the RAS or the CCNE1/WNT1 clusters whose expression change correlated with CNAs and showed differential expression in comparison with R2 and shp53 HMECs. Ninety (90) genes (36 overexpressed with copy number gains and 54 underexpressed and copy loss) fitted these criteria in shp53-RAS HMECs and 156 genes (64 overexpressed and gained, 92 underexpressed and lost) in shp53-CCNE1/shp53-WNT1 (Supporting Information Table1). Noticeably, only 4 genes (1.7%) were found in both the shp53-RAS and in the shp53-CCNE1/shp53-WNT1 lists (Supporting Information Fig.9A ). Such a small overlap could not have happened by chance (hypergeometric test, p=0.75).
We selected annotated cancer genes (oncogenes and tumor suppressors) or genes belonging to the RAS pathway ( Fig.4A and Supporting Information Table 1 ). In the shp53-RAS cluster, we identified 5 known oncogenes that were gained and over-expressed (ERBB2, HEY1, PLAG1, ZBTB10, CRTC3) , and 6 genes lost and under-expressed. Of these 6 genes, 4 were part of the RAS pathway (TMEM154, LRAT, AKAP6, MTUS1) and 2 were tumor suppressors (FBXW7, SERPINB5). FBXW7 is a negative regulator of oncogenic transcription factors such as MYC, FOS or NOTCH 27 , whereas SERPINB5 (MASPIN) is described as a metastasis suppressor in breast and other cancers 28 .
In the shp53-CCNE1/shp53-WNT1 cluster, we identified 13 genes, 5 gained and over-expressed, 8 lost and under-expressed ( Fig.4A) , all of which classified as cancer genes. Of the 5 gained and over-expressed genes, NUMA1, PMS2 and CUX1 have well documented roles in mitotic spindle assembly or DNA repair and STAT3 is a key signaling node for a number of growth factors and cytokines frequently involved in cancer 29 . PLAG1
was selected both in the RAS and CCNE1/WNT1 upregulated genes, but its expression level was 9 times higher in shp53-RAS compared to shp53-CCNE1/shp53-WNT1. Of the 8 lost and under-expressed genes, we noted LATS1, negative regulator of the Hippo pathway, CTNNB1 (β-catenin), FYN homolog of SRC and TGFBR2.
Using a similar approach, we also searched for genes whose expression was impacted by CpG methylation.
We restricted our analysis to DMRs located close to transcription start sites (TSS) of annotated genes showing at least a 20% change in methylation, associated to a 2fold variation in mRNA expression level ( Fig.4B) . Again, genes modified by DNA methylation in the shp53-RAS cluster showed little overlap with those in shp53-CCNE1/shp53-WNT1 HMECs (Hypergeometric test, p =0.66, Supporting Information Fig.9B ).
Of the 17 genes hypermethylated and underexpressed in the shp53-RAS cluster, 7 were key in cell-adhesion and the epithelial phenotype (KRT5, ITGB4, DMKN, PKP3, ACP, PROM2, KDF1). Interestingly, 4 genes were hypomethylated and overexpressed, of which 2 (ITGBL1, FRMD4A) corresponded to genes involved in cell invasion and metastasis 30, 31 . In the shp53-CCNE1/shp53-WNT1 HMECs, 16 genes all hypermethylated and downregulated were identified (Fig.4B) , including 4 genes related to cell invasion or EMT (ANGPTL4, ITGB3, EHD3, FBN2). Interestingly, ITGB3 and EHD3, interact physically in an activating regulatory loop.
Altogether, the RAS and the CCNE1/WNT1 transformed HMECs showed clear differences in genes whose expression was impacted by either CNAs or CpG methylation. The principal features in RAS HMECs were the repression of genes associated with the epithelial phenotype and cell adhesion and conversely the activation of genes favoring cell invasion. In clear contrast, CCNE1/WNT1 HMECs showed a downregulation of EMT or invasion associated genes, combined with the activation of DNA repair and cell division genes.
These results indicate the activation of distinct pathways in the respective sublines, with an opposite trend concerning cell phenotype, pro-mesenchymal in shp53-RAS and pro-epithelial in shp53-CCNE1/shp53-WNT1.
RAS and CCNE1/WNT1 HMECs resemble claudin-low and Basal-like breast cancer, respectively
We wanted to determine how much our HMEC models paralleled with human breast cancer. Our 16 HMEC models were classified as Basal-like breast cancer according to the CIT and PAM50 32 classifiers (Supporting Information Fig.10A ). Noticeably, shp53-RAS were classified as Claudin-low and shp53-CCNE1 and shp53-WNT1 as epithelial basal-like ( Fig.5A ). Next, we sought to compare the characteristics of our HMEC models with that of the Claudin-low and the Basal-like subgroups in the human primary breast cancer METABRIC dataset. Restricting our analysis to TP53 mutated and Basal-like of the invasive ductal carcinoma type, we selected 225 tumors, which we stratified in Claudin-low/Basal-like (63) and Basal-like/Non-Claudin-low (162) subsets. We determined that the KRAS pathway was among the top activated pathways in Claudinlow/Basal-like tumors (Supporting Information Fig.10B-C) , and that Basal-like/Non-Claudin-low tumors presented a significantly higher incidence of CNAs and increased levels of CCNE1 expression ( Fig.5B-C-D) .
These data suggested that the differences in genomic profiles induced by distinct oncogenes observed in our HMEC models mimicked situations occurring in spontaneous human breast tumors: fewer genomic changes and elevated RAS in mesenchymal like claudin-low basal tumors, in comparison to non-claudin-low basal tumors which show more rearrangements and frequent CCNE1 overexpression.
Discussion
Breast cancer can be broken down in at least 5 molecular subtypes on the basis of differences in mRNA expression and genetic anomaly profiles 9, 10 . It is generally assumed that the origin of these molecular subtypes lies in cell lineage differences, where the original tumorigenic insult took place 8, 9 . It is, however, of note that basal-like tumors from BRCA1 mutated patients were shown to originate from luminal progenitor cells 33, 34 , which undergo a differentiation shift from luminal to basal cells, giving rise to basallike rather than luminal tumors 35 . Similarly, expression of an activated PikcaH1047R allele in committed unipotent luminal cells in mouse mammary glands induced cell fate reprogramming and emergence of basal like tumors 36 . Furthermore, mammary tumors from genetically modified mice were shown to bear different CNA profiles according to the driver mutation that initiated the tumor 37 . Altogether, these data suggest that founding oncogenic mutations can also impinge on the genetic profile of breast cancers.
Using primary HMECs, that classified as luminal progenitors 33 (Supporting Information Fig.10E ), we show that cell transformation by way of distinct oncogenes resulted in different patterns of aberrations at both the CNA and DNA methylation levels, as well as distinct phenotypes. Most remarkably, HMECs transformed by RASv12 (shp53-RAS) presented clearly distinct patterns of genetic and epigenetic modifications compared to their shp53-CCNE1 or shp53-WNT1 counterparts. The latter two exhibited globally similar CNA and DNA methylation profiles, albeit some focal differences could be found.
In our model system, inactivation of the TP53 gene was the initial step towards transformation. Given the role of TP53 in genome integrity, onset of genetic instability was expected in shp53 HMECs, but no gross genomic anomalies were observed, even after more than one year in culture. However, shp53 HMECs rapidly became tetraploid, in line with the critical role of p53 in ploidy control 38 . Tetraploidy is considered as a prelude to large scale chromosomal aberrations in cancer [39] [40] [41] . Whole genome sequencing of cancer showed that whole genome doubling (WGD) was an early event in over 40% of breast cancers and occurred significantly more frequently in TP53 mutated compared with TP53 wild type tumors 42 . Thus, in our HMEC models p53 inactivation did not result in structural rearrangements, but favored genetic plasticity and laid the ground for genetic anomalies that occurred upon oncogene expression. Noticeably, shp53-CCNE1 and shp53-WNT1 became aneuploid and showed a significant increase in rearrangement levels after soft agar cloning. In remarkable contrast, shp53-RAS remained strictly tetraploid and did not acquire further anomalies after soft agar. These results, together with reduced numbers of γH2Ax and 53BP1 foci in shp53-RAS, compared with shp53-CCNE1 or shp53-WNT1, indicated lower levels of genetic instability in RAS relative to CCNE1 or WNT1 HMECs. These observations are in line with recent work showing that primary mammary epithelial cells or immortalized HME expressing high levels of ZEB1 kept stable genomes upon transduction of RASv12 43 . In this model system, ZEB1 was shown to control a ROS scavenging program that protected cells overexpressing RASv12 from DNA damage. The relative genetic stability of shp53-RAS HMECs could be linked to the strong EMT, associated with the activation of ZEB1, that characterized these cells (Fig.5A) . In contrast, shp53-CCNE1 and shp53-WNT1 HMECs showed an epithelial phenotype and low levels of ZEB1 expression.
In this work, we inferred a chronology of the genetic changes that occurred at different steps of HMEC transformation. The first modified were miR and mRNA expression, followed by DNA methylation, while CNAs occurred last. This suggested that expression changes acted as drivers, modified the phenotype and impacted on the epigenetic and genetic landscape that finally locked the changes. In shp53-RAS HMECs is clear that HMEC models do not sum up the complete spectrum of human breast cancers, however our data show that they mimic, at least partially, Basal-like and Claudin-low breast cancer. In conclusion, our data show that early activation of distinct oncogenic insults in a given cell type will not only impinge on the phenotypic characteristics of the resulting tumors, but also impact on their genomic and epigenetic landscapes. Indeed, the genes whose expression was modified either by DNA methylation or CNAs in our models were consistent with the dominant pathways activated and reflected the phenotypes of the respective models, mesenchymal in shp53-RAS, epithelial in shp53-CCNE1/shp53-WNT1 (Fig.6 ). (bottom table) . shp53-CCNE1 and shp53-WNT1 sublines present a significantly higher number of double strand breaks than shp53-RAS. Fig.4: HMEC models form 3 clusters based on the oncogene transduced. Fig.5 : CNA plots of HMEC models. A: CNA at different steps of transformation. CNAs are represented for each chromosome, red for losses, blue for gains. The hight of the bars indicates the probability of occurrence. B: cumulated CNA plots of HMEC models. CNAs are represented for each chromosome, red for losses, blue for gains. The hight of the bars indicates the amplitude of the copy number change. Fig.6 : density histograms of RRBS methylation scores at CpGs sites (at least 5 contiguous CG) genome wide in primary R2 HMECs, shp53.Early, shp53.Late, shp53-CCNE1, shp53-CCNE1.SA (Soft Agar), shp53-WNT1, shp53-WNT1.SA, shp53-RAS, shp53-RAS.SA Supplementary Fig.7 : principal pathways and regulation networks differentially expressed in the RAS compared with the WNT/CCNE cluster. Adifferential pathways at the level of miR expression; the 81 miR contributing the most to the definition of first axis of the PCA in Fig 3c were used, the log value indicates the significance level. We selected the top 3 pathways. Bdifferential pathways at the level of mRNA expression; the 185 genes contributing the most to the definition of the first axis of the PCA in Fig 3e were Supporting Information Fig.8 : phenotypic characteristics of shp53 HMEC sublines. Cells were stained by immunofluorescence (IF) for the expression of ECAD (E-Cadherin, green) which is a marker of epithelial cells, VIM (Vimentin, red) marker of mesenchymal cells, CK8 (Cytokeratin 8) marker of luminal breast epithelial cells, CK5 (Cytokeratin 5) marker of basal breast epithelial cells. Differential expression patterns can be observed according to the genetic elements expressed and the stage of the culture. Normal HMEC and Early shp53 co-express ECAD and VIM and are mosaiec for CK5 and CK8 expression. In shp53 late HMEC tended to lose ECAD expression and become mesenchymal, but kept a mosaic CK5/CK8 pattern. In shp53-WNT1 and shp53-CCNE1 ECAD and VIM were co-expressed in all cells indicating the conservation of an epithelial phenotype. Interestingly, whereas shp53-WNT1 expressed only CK5 and no CK8, shp53-CCNE1 preserved the original mosaic phenotype of the shp53 HMECs. Expression of RAS-v12 produced drastic changes as illustrated by the concomitant loss of expression of ECAD and both CK5 and CK8. Fig.9 : Genes modified by CNA or differential methylation in shp53-RAS and shp53-CCNE1/ shp53-WNT1 show little overlap. Of note MTUS1 is strongly underexpressed in RAS (-2,95; about 1/10 x) whereas it is overexpressed in CW (0,87, about 1,8 x). PLAG1 is strongly overexpressed in RAS (3,25; about 9,5 X) and moderately in CW (0,84 about 1,8 x) similarly to THRA (RAS change =1,89 about 3,7x; CW change =0,89 about 1,85x). ZNF7 expression change is equivalent in both clusters. Fig.10: HMEC models 
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